Caspase-1 activated in inflammasomes triggers a programmed necrosis called pyroptosis, which is mediated by gasdermin D (GSDMD). However, GSDMD-deficient cells are still susceptible to caspase-1-mediated cell death. Therefore, here, we investigate the mechanism of caspase-1-initiated cell death in GSDMD-deficient cells. Inflammasome stimuli induce apoptosis accompanied by caspase-3 activation in GSDMD-deficient macrophages, which largely relies on caspase-1. Chemical dimerization of caspase-1 induces pyroptosis in GSDMD-sufficient cells, but apoptosis in GSDMD-deficient cells. Caspase-1-induced apoptosis involves the Bid-caspase-9-caspase-3 axis, which can be followed by GSDME-dependent secondary necrosis/pyroptosis. However, Bid ablation does not completely abolish the cell death, suggesting the existence of an additional mechanism. Furthermore, cortical neurons and mast cells exhibit little or low GSDMD expression and undergo apoptosis after oxygen glucose deprivation and nigericin stimulation, respectively, in a caspase-1- and Bid-dependent manner. This study clarifies the molecular mechanism and biological roles of caspase-1-induced apoptosis in GSDMD-low/null cell types.
Caspases are a family of cysteine proteases that mediate regulated cell death, including apoptosis and pyroptosis1. To date, 13 caspases have been identified in mammals (these exclude caspase-11, which is now called mouse caspase-4, and caspase-13, which was a misnomer for bovine caspase-4). While most caspases act in apoptosis as initiators or effectors, several inflammatory caspases, such as caspase-1, caspase-4 (caspase-11 in mice), and caspase-5, trigger pyroptosis2,3,4. Apoptosis and pyroptosis are different morphologically, functionally, and mechanistically. For example, while the loss of membrane integrity is a late event in apoptosis, pyroptosis is a lytic cell death accompanied by rapid cell-membrane rupture2,3,4,5. Caspase-3, -7, and -6 serve as effector caspases in apoptosis and induce phosphatidylserine (PS) externalization, cell shrinkage, membrane blebbing, and DNA fragmentation by cleaving so-called death substrates2,3. In pyroptosis, pores are formed in the cell membrane, which cause water influx and cell swelling, resulting in cell-membrane rupture4,6. Pyroptotic cells release cellular contents, including inflammatory cytokines and damage-associated molecular patterns (DAMPs), so pyroptosis is thought to be more inflammatory and immunogenic than apoptosis2,3,4. Pyroptosis has been suggested to contribute to host defense against microbial infections7,8,9, while it has also been implicated in the pathogenesis of diseases, such as endotoxin shock and acquired immune deficiency syndrome10,11.
Caspase-1 is activated in inflammasomes, which are multiprotein oligomers composed of a certain intracellular pattern recognition receptor (PRR), the adaptor apoptosis-associated speck-like protein containing a caspase recruitment domain(ASC), and pro-caspase-14,12. Inflammasome-forming PRRs, including NLR family pyrin domain containing 3 (NLRP3), NLR family CARD domain containing 4 (NLRC4) and absent in melanoma 2 (AIM2), respond to specific ligands or activators that facilitate the assembly of inflammasomes, in which pro-caspase-1 molecules are brought into close proximity, resulting in caspase-1 activation4,12,13. While NLRP3 and AIM2’s binding to pro-caspase-1 requires ASC, NLRC4 can bind to pro-caspase-1 directly, thereby inducing pyroptosis independent of ASC4,12,14. On the other hand, caspase-11, -4, and -5 directly bind to cytoplasmic lipopolysaccharide (LPS), leading to the oligomerization and activation of these caspases; thus, these caspases serve as sensor molecules for intracellular LPS15,16,17.
Recently, gasdermin D (GSDMD) was identified as a critical mediator of pyroptosis18,19,20. Active caspase-1, -4, -5, and -11 cleave GSDMD within a linker between its N-terminal and C-terminal domains. After cleavage, the N-terminal domain forms pores in the cell membrane to cause pyroptosis21,22,23. The C-terminal domain of GSDMD inhibits the pore-forming activity of the N-terminal domain21,22,23, and it is speculated that GSDMD’s cleavage by inflammatory caspases relieves the N-terminal domain from this autoinhibition. The cell death caused by intracellular LPS was shown to be completely abrogated in the absence of GSDMD18,19,20, suggesting that GSDMD is the sole mechanism by which the LPS-sensing caspases (caspase-11, -4, and -5) trigger cell death. By contrast, caspase-1 has been suggested to participate in both GSDMD-dependent and GSDMD-independent cell death pathways, given that inflammasome stimuli can induce cell death in GSDMD-deficient cells19,20. However, the GSDMD-independent cell death pathway is not well understood. Moreover, it is still controversial whether this pathway relies on caspase-1, because inflammasome formation results in not only the activation of caspase-1 but also that of caspase-8 via ASC speck formation24. In fact, ASC-dependent caspase-8-mediated apoptosis was observed when caspase-1-deficient cells were stimulated with inflammasome activators25. Hence, it is also conceivable that caspase-8 mediates the GSDMD-independent cell death observed after inflammasome formation in the absence of GSDMD. Thus, based on the current evidence, it remains unclear whether and how caspase-1 induces cell death independent of GSDMD.
In this study, we investigate caspase-1-induced cell death pathways. Our results clearly demonstrate that caspase-1 can initiate apoptosis in the absence of GSDMD. Moreover, we find that the caspase-1-induced apoptosis involves the Bid-caspase-9-caspase-3 axis, which can elicit secondary necrosis/pyroptosis mediated by GSDME (also known as DFNA5). Furthermore, GSDMD appears to inhibit the caspase-1-initiated apoptosis in a manner involving its pore-forming activity. Thus, this study reveals the complex caspase-1-induced cell death mechanisms. Notably, in early studies, caspase-1 was considered a pro-apoptotic caspase;26,27,28,29 however, caspase-1’s induction of apoptosis is not as well established as its role in pyroptosis. This study also sheds light on this neglected aspect of caspase-1.
Caspase-1 mediates apoptosis in GSDMD-deficient macrophages
To determine whether caspase-1 induces cell death in the absence of GSDMD, thioglycolate-elicited peritoneal macrophages (TEPMs) and bone marrow-derived macrophages (BMMs) from wild-type (WT), Gsdmd−/−, Pycard (the gene for ASC)−/−, and Casp1−/− mice were stimulated with inflammasome activators, and cell death was assessed by lactate dehydrogenase (LDH) release from the cells. Transfection with poly(dA:dT), which activates the AIM2 inflammsome13, induced rapid LDH release from WT TEPMs indicating that pyroptosis was induced, but not from Pycard−/− or Casp1−/− TEPMs within the same time window (Fig. 1a). Importantly, a delayed but significant LDH release was observed when the Gsdmd−/− TEPMs were transfected with poly(dA:dT). Similarly, when BMMs were infected with Salmonella (S.) Typhimurium, which activates the NLRC4 inflammasome30, the Gsdmd−/− BMMs released LDH more rapidly than did the Casp1−/− BMMs (Fig. 1b). These results indicated that inflammasome formation can lead to caspase-1 dependent cell death even in the absence of GSDMD. As expected, two hours after S. Typhimurium infection, the WT BMMs showed a pyroptotic morphology (Fig. 1c). On the other hand, apoptotic morphological changes, such as membrane blebbing2,3, were induced in the Gsdmd−/− BMMs, but not in the WT or Casp1−/− BMMs (Fig. 1c). The p10 subunit of mature caspase-1 was detected in culture supernatants plus cell lysates of the WT and Gsdmd−/− BMMs after S. Typhimurium infection (Fig. 1d). Notably, S. Typhimurium infection strongly induced the activation of caspase-3, caspase-8, and caspase-9 in the Gsdmd−/− BMMs (Fig. 1d). By contrast, cleaved forms of these caspases were not or only barely detected in the WT and Casp1−/− BMMs. These results suggested that GSDMD-deficient macrophages undergo caspase-1-dependent apoptosis after inflammasome formation.
To exclude the possible involvement of the ASC-caspase-8 pathway in the S. Typhimurium-induced cell death of GSDMD-deficient macrophages, we used RAW264.7 cells, a macrophage-like cell line that lacks ASC expression (Supplementary Fig. 1)31. Just like the BMMs, while WT RAW264.7 cells died by pyroptosis after S. Typhimurium infection, the Gsdmd knockout (KO) RAW264.7 cell clones exhibited apoptotic features including membrane blebbing and caspase-3 activation (Fig. 1e–g). These responses were not seen in Casp1/Gsdmd-double KO (DKO) cells. In addition, consistent with a recent report32, caspase-3 activation, apoptotic morphological changes, and LDH release were observed in the Gsdmd-KO cells after treatment with Val-boroPro, a recently described inducer of caspase-1 activation33 (Supplementary Fig. 2a–c). Importantly, these responses were also abrogated in Casp1/Gsdmd-DKO cells (Supplementary Fig. 2a–c). These results collectively indicated that caspase-1 can trigger apoptosis in the absence of GSDMD.
Caspase-1 initiates apoptosis in GSDMD-deficient cells
To examine caspase-1’s ability to induce apoptosis directly, we constructed a recombinant mouse procaspase-1, and procaspase-8 as a control, fused with the three tandem N-terminal Fv domains (hereafter Fv3-mCasp1 and Fv3-mCasp8, respectively), which interact with the bivalent chemical compound AP20187 (Fig. 2a)34,35. Fv3-mCasp1 and Fv3-mCasp8 are oligomerized and activated in the presence of AP20187. Colon-26 murine colorectal carcinoma cells, which express GSDMD but not ASC (Supplementary Fig. 1), were stably transfected with Fv3-mCasp1 (CL26-iCasp1 cells) or Fv3-mCasp8 (CL26-iCasp8 cells). As expected, the former and the latter underwent necrotic and apoptotic cell death, respectively, after AP20187 treatment (Supplementary Fig. 3a, Supplementary Movie 1). Depletion (knockdown and KO) of GSDMD significantly delayed but did not completely block the LDH release from AP20187-treated CL26-iCasp1 cells (Fig. 2b–d, Supplementary Fig. 3b). AP20187 induced caspase-3 activation in the Gsdmd-KO but not WT cells (Fig. 2c and Supplementary Fig. 3d). In addition, PS externalization and plasma membrane blebbing before plasma membrane permeabilization, hallmarks of apoptosis2,3, was observed in the AP20187-treated Gsdmd-KO CL26-iCasp1 cells (Fig. 2e, f, and Supplementary Fig. 3c, Supplementary Movie 2).
Moreover, the reconstitution of GSDMD expression in Gsdmd-KO CL26-iCasp1 cells abolished the activation of caspase-3 (Fig. 2c and Supplementary Fig. 3e) and restored the early LDH release (1.5 h after AP20187 treatment) (Fig. 2d). GSDMD-reconstituted cells, like WT cells, exhibited a necrotic morphology with a loss of cell membrane integrity quickly after AP20187 treatment (Fig. 2e, f). These results clearly indicated that caspase-1 can initiate both pyroptosis and apoptosis, depending on the expression of GSDMD. Interestingly, reconstitution with the I125N mutant of GSDMD, whose pore-forming activity is severely attenuated19,23, did not have these effects (Fig. 2c, e), suggesting that the pore-forming activity of GSDMD determines whether pyroptosis or apoptosis will occur downstream of caspase-1 activation.
We also found that ATP, a DAMP that induces chemotaxis and activation of the NLRP3 inflammasome in macrophages2,4, was released from GSDMD-expressing cells, but not from Gsdmd-KO cells, immediately after AP20187 treatment (Fig. 2g). The ATP release occurred prior to LDH release (Supplementary Fig. 3f), suggesting that ATP is released through the GSDMD-formed pores before cell lysis.
Caspase-1-induced apoptosis depends on caspase-3
Although caspase-3 plays a central role in apoptosis, caspase-3-independent apoptosis has also been described in previous studies36,37. Using SCAT3, a fluorescence resonance energy transfer (FRET) probe that detects caspase-3 activation38, we observed that caspase-3 was activated along with the apoptotic morphological changes induced by AP20187 in Gsdmd-KO CL26-iCasp1 cells (Supplementary Fig. 4a). Moreover, the ablation of caspase-3 almost completely abrogated the LDH release and PS exposure induced by AP20187 (Fig. 3a–c and Supplementary Fig. 4b), indicating that the caspase-1-induced apoptosis depends on caspase-3. Consistent with the results obtained using Gsdmd-KO CL26-iCasp1 cells, the apoptotic morphological changes induced in Gsdmd-KO RAW264.7 cells by S. Typhimurium or Val-boroPro were also abolished when caspase-3 was depleted (Fig. 3d, e and Supplementary Fig. 4c), indicating that caspase-1 induces caspase-3-dependent apoptosis in macrophages in the absence of GSDMD.
GSDME mediates necrosis after caspase-1-induced apoptosis
Given that caspase-1 activation induces apoptosis in the absence of GSDMD, LDH release from Gsdmd-KO cells induced by caspase-1 activation is likely to be a result of secondary necrosis. Because LDH release was observed as rapid as 2 h after S. Typhimurium infection in Gsdmd−/− BMMs (Fig. 1b) and 1.5 h after AP20187 treatment of Gsdmd-KO CL26-iCasp1 cells (Fig. 2b), one may wonder if caspase-1-initiated apoptosis might proceed to the secondary necrosis stage more rapidly than regular (e.g. caspase-8-initiated) apoptosis. However, the time intervals between caspase-3/7 activation and LDH release in these instances of caspase-1-initiated apoptosis was similar to the intervals in cspase-8-initiated apoptosis induced by Fas ligand plus cycloheximide treatment in Gsdmd−/− BMMs and that induced by AP20187 treatment in CL26-iCasp8 cells (Supplementary Fig. 4d–g). Thus, the speed at which the cell death process proceeds to secondary necrosis was similar between caspase-1 and caspase-8-initiated apoptosis.
Recently, caspase-3 was demonstrated to cleave GSDME, to induce a secondary necrosis/pyroptosis39,40. Indeed, GSDME was cleaved in a caspase-3-dependent manner in Gsdmd-KO CL26-iCasp1 cells after AP20187 treatment (Fig. 3a). We found that the KO of GSDME in Gsdmd-KO CL26-iCasp1 cells severely reduced the cell membrane damage observed within 4 h after AP20187 treatment, as determined by LDH release and staining with the cell-impermeant fluorescent dyes propidium iodide and YO-PRO-1 (Fig. 3f, g; Supplementary Fig. 5a–d; Supplementary Movie 3), while GSDME ablation did not affect the PS exposure, membrane blebbing, or caspase-3 activation in the Gsdmd-CL26-iCasp1 cells (Fig. 3g and Supplementary Fig. 5b–d). However, Gsdmd/Gsdme-DKO CL26-iCasp1 cells became necrotic, and extensive LDH release was observed by 24 h after AP20187 treatment (Supplementary Fig. 5e–g). These results indicated that GSDME mediates a rapid secondary necrosis/pyroptosis after the caspase-1-induced apoptosis, but is not essential for the cell lysis at later times. GSDME was also cleaved in GSDMD-deficient BMMs after S. Typhimurium infection (Supplementary Fig. 5h). However, the role of GSDME in BMM apoptosis has been controversial39,41. RAW264.7 cells expressed little GSDME (Supplementary Fig. 1), and thus this cell line is not suitable to test the role of GSDME in the secondary necrosis/pyroptosis. Thus, further experiments using BMMs from Gsdmd/Gsdme-DKO mice are required to determine the contribution of GSDME in the secondary necrosis/pyroptosis of GSDMD-deficient macrophages.
Caspase-1-induced apoptosis involves caspase-9
Next, we examined the possible involvement of other caspases in the caspase-1-initiated apoptosis in GSCMD-deficient cells. The proteolytic activation of caspase-2, -7, -8, and -9 was observed in the AP20187-treated Gsdmd-KO CL26-iCasp1 cells (Fig. 4a, b). The cleavage of caspase-8 (generation of the p18 fragment) and caspase-2 (generation of the p30 fragment) observed in Gsdmd-KO CL26-iCasp1 after AP20187 treatment and in RAW264.7 cells after S. Typhimurium infection was almost completely abrogated in the Gsdmd/Casp3-DKO cell lines (Fig. 4c–e). The cleavage of caspase-7 (generation of the p20 fragment) and caspase-9 (generation of the p37 fragment) was also reduced in the Gsdmd/Casp3-DKO cells compared to Gsdmd-KO cells; however, residual activation of caspase-7 and -9 was reproducibly observed in the Gsdmd/Casp3-DKO cells (Fig. 4c, e). These results indicated that caspase-2 and -8 are activated downstream of caspase-3, whereas caspase-7 and -9 can be activated both independently of (upstream of or in parallel with) and downstream of caspase-3 in Gsdmd-KO cells under these experimental conditions.
We next set out to identify caspases involved in the caspase-1-induced apoptosis. Depleting caspase-2, -6, or -7 from the Gsdmd-KO CL26-iCasp1 cells did not affect the apoptosis induced by AP20187 (Fig. 4f, g and Supplementary Fig. 6a). Gsdmd/Rip3k-DKO CL26-iCasp1 cells were then used to generate Casp8-KO cells to prevent necroptosis induction. The Gsdmd/Rip3k-DKO and Gsdmd/Rip3k/Casp8-triple KO cell lines underwent apoptosis normally after AP20187 treatment (Fig. 4h, i and Supplementary Fig. 6b), indicating that the caspase-1-induced apoptosis can proceed independently of these caspases. By contrast, depleting caspase-9 from the Gsdmd-KO CL26-iCasp1 cells markedly reduced the activation of caspase-3 and GSDME, PS exposure, and LDH release induced by AP20187 treatment (Fig. 5a–d), which were restored by complementation with the Casp9 cDNA (Fig. 5e and Supplementary Fig. 7a, b), indicating that caspase-9 mediates the apoptosis initiated by caspase-1.
Bid plays a critical role in caspase-1-induced apoptosis
A central mechanism in the activation of caspase-9 is the formation of an apoptosome after the release of cytochrome c from mitochondria into the cytoplasm2,3. Cytochrome c release into the cytosol, mitochondrial depolarization, and formation of an Apaf-1-caspase-9 complex were observed in Gsdmd-KO CL26-iCasp1 cells after AP20187 treatment (Fig. 6a and Supplementary Fig. 8a, b). Bcl-2 homology 3 (BH3)-only proteins are known to cause cytochrome c release2. Among the BH3-only family members, Bid was previously shown to be cleaved into its active form, truncated Bid (tBid) by caspase-1 in vitro42. We observed the processing of Bid into tBid in WT and Gsdmd-KO CL26-iCasp1 cells treated with AP20187, and tBid was released from the cells in a GSDMD-dependent manner (Fig. 6b). Remarkably, cytochrome c release, mitochondrial depolarization, and Apaf-1-caspase-9 complex formation were not induced by AP20187 until 1 h after AP20187 treatment if Bid was ablated (Fig. 6a, Supplementary Fig. 8a, b, and Supplementary Fig. 9a). Moreover, the depletion of Bid severely impaired the LDH release from Gsdmd-KO CL26-iCasp1 cells at least up to 4 h after AP20187 treatment (Fig. 6c). Under the same conditions, caspase-3 activation and PS exposure were also severely diminished until 1.5 h after AP20187 treatment (Fig. 6d and Supplementary Fig. 9b, c). Furthermore, knockdown of Bax/Bak, pro-apoptotic partners of Bid, significantly reduced the activation of caspase-3 (Supplementary Fig. 8c–f) without affecting tBid generation. These results indicate that Bid plays a critical role in the caspase-1-induced cell death through the intrinsic apoptosis pathway in the absence of GSDMD.
Asp 59 of Bid was previously shown to be the cleavage site of caspase-1, whereas Asp 75 was the site for granzyme B42. The reconstitution of Gsdmd/Bid-DKO CL26-iCasp1 cells with WT or the D75A mutant of Bid restored the tBid generation, caspase-3 activation, LDH release, and PS exposure in response to AP20187 treatment (Fig. 6e–g and Supplementary Fig. 9d). However, the D59A mutant of Bid failed to restore these responses, indicating that caspase-1 cleaves Bid at Asp 59 to induce apoptosis. tBid was also produced in Gsdmd−/− BMMs during S. Typhimurium infection, while it was poorly produced in Casp1−/− BMMs (Fig. 7a). Knockdown of Bid suppressed the S. Typhimurium-induced caspase-3 activation (Fig. 7b), and diminished the apoptotic morphological changes in Gsdmd-/- BMMs (Fig. 7c). Consistently, Gsdmd/Bid-DKO BMMs showed reduced caspase-3 activation and LDH release compared to Gsdmd−/− BMMs during S. Typhimurium infection (Fig. 7d, e). S. Typhimurium infection and Val-boroPro treatment induced tBid production in Gsdmd-KO RAW264.7 cells, but not in Gsdmd/Casp1-DKO cells (Fig. 7f and Supplementary Fig. 10a). Caspase-3 activation and apoptotic morphological changes were induced in Gsdmd-KO RAW264.7 cells by S. Typhimurium and Val-boroPro, but were suppressed by the ablation of Bid (Fig. 7g, h and Supplementary Fig. 10b, c). In addition, the LDH release induced by Val-boroPro was significantly lower in Gsdmd/Bid-DKO RAW264.7 cells than in the Gsdmd-KO RAW264.7 cells (Supplementary Fig. 10d). From these results, we concluded that Bid is involved in the caspase-1-induced apoptosis in multiple cell types. The tBid production induced by caspase-1-activating agents was not affected by the depletion of caspase-3 or caspase-9 (Fig. 7g, Supplementary Fig. 9e, f and Supplementary Fig. 10b), indicating that Bid is upstream of these caspases.
Then we tested the effect of caspase-1-induced apoptosis on the fate of S. Typhimurium in macrophages, the number of intracellular bacteria was determined by gentamicin protection assay (Supplementary Fig. 11). S. Typhimurium persisted in Casp1−/− BMMs more than in WT and Gsdmd−/− BMMs (Supplementary Fig. 11a). S. Typhimurium could grow in Gsdmd/Casp1-DKO and Gsdmd/Bid-DKO RAW264.7 cells but not in WT and Gsdmd-KO RAW264.7 cells (Supplementary Fig. 11b). These results suggest that caspase-1-induced Bid-dependent apoptosis can contribute to the suppression of intracellular bacterial growth/survival in the absence of GSDMD.
A Bid-independent pathway that is sensitive to CA-074 Me
Although Bid played a critical role in the caspase-1-induced apoptosis and GSDME cleavage at early time points, Gsdmd/Bid-DKO CL26-iCasp1 cells showed caspase-3 and caspase-9 activation, GSDME cleavage, PS exposure, plasma membrane blebbing, and LDH release when the AP20187 treatment was prolonged (Fig. 8a–c and Supplementary Fig. 12a–c). Depletion of caspase-3 from the CL26-iCasp1 cells diminished GSDME cleavage, PS exposure, LDH release, and loss of viability (Fig. 8b and Supplementary Fig. 12b–d). These observations suggested that a Bid-independent pathway exists that transduces caspase-1 activation to apoptosis in a caspase-3-dependent manner. Similarly, the Gsdmd/Casp9-DKO CL26-iCasp1 cells died after an 8-h incubation with AP20187 (Fig. 8d). We found that Z-VAD-FMK, a pan-caspase inhibitor, and CA-074 Me, a cathepsin B inhibitor, suppressed the LDH release from Gsdmd/Bid-DKO CL26-iCasp1 cells treated with AP20187 for 8 h (Fig. 8e). CA-074 Me significantly reduced the LDH release and caspase-3 activation in Gsdmd/Bid-DKO cells, while it had no or only a marginal effect on these responses in Gsdmd-KO cells (Fig. 8f, g), suggesting that the inhibitory effect of CA-074 Me is specific for the Bid-independent pathway.
In Raw264.7 cells, unlike in CL26-iCasp1 cells, the involvement of the Bid-independent pathway in caspase-1-mediated apoptosis might be limited as Gsdmd/Bid-DKO Raw264.7 cells were highly protected from cell death even at 24 h after the Val-boroPro treatment (Supplementary Fig. 10d). Further experiments using Gsdmd/Bid-DKO mice are required to evaluate the importance of the Bid-independent pathway in macrophages.
Caspase-1 induces apoptosis in naturally GSDMD null cells
We next sought to ask whether caspase-1 would induce apoptosis in naturally GSDMD negative cells. To this end, we first employed L929 cells that do not express GSDMD (Supplementary Fig. 1). L929 cells transduced with Fv3-mCasp1 (L929-iCasp1 cells) underwent apoptosis accompanied with caspase-3 and Bid processing after AP20187 treatment (Fig. 9a–c). Ectopic expression of GSDMD changed the form of cell death in the L929-iCasp1 cells into pyroptosis (Fig. 9c–e), confirming that GSDMD determined the mode of caspase-1-induced cell death.
The above results suggest that activation of caspase-1 would induce apoptosis in caspase-1 positive but GSDMD negative or low cells under more physiologically or pathologically relevant conditions (Supplementary Fig. 13a). Analysis of a genome-wide expression dataset (GNF Mouse GeneAtlas V3) revealed that the GSDMD expression is high in macrophages and the small intestine in mice (Supplementary Fig. 13b). On the other hand, GSDMD is weakly expressed in the epidermis, mammary gland, mast cells, and marginal zone B cells, whereas caspase-1 is expressed at high levels in the same samples (Supplementary Fig. 13b). Moreover, the GSDMD expression was very low in the spinal cord compared to the TEPMs, spleen, and RAW264.7 cells at the protein and mRNA levels, while the pro-caspase-1 and Bid proteins and the Gsdme gene transcript were detected in the same spinal cord specimens (Supplementary Fig. 13c–e). Thus, there are cell types that express caspase-1 without expressing substantial levels of GSDMD, in which caspase-1-induced apoptosis may occur. Moreover, primary cortical neurons have been demonstrated to undergo apoptosis accompanied with Bid cleavage in a caspase-1-dependent manner after oxygen/glucose deprivation (OGD)28. We found that GSDMD was not expressed in primary cortical neurons (Fig. 10a and Supplementary Fig. 13f). Consistent with the previous study, OGD induced the activation of caspase-3 and apoptosis accompanied with nuclear pyknosis and karyorrhexis in cortical neurons (Fig. 10b and Supplementary Fig. 13g). Furthermore, the OGD-induced apoptosis was diminished in the absence of caspase-1 or Bid (Fig. 10b). We also prepared bone marrow-derived mast cells (Fig. 10c). GSDMD mRNA levels were significantly lower in the cells than in BMMs (Fig. 10a). Stimulation with nigericin, an activator of the NLRP3 inflammasome, induced PS exposure and cell death in LPS-primed mast cells from WT mice, but not those lacking caspase-1 (Fig. 10d). Also, the activation of caspase-1 and caspase-3, tBid production, and GSDME maturation were induced during nigericin treatment, which are diminished in Casp1−/− mast cells (Fig. 10e). Mature GSDMD (the p30 fragment) was only faintly detected in nigericin-treated mast cells, while inactive p43 and p21 fragments of GSDMD were generated (Fig. 10f), suggesting that full-length GSDMD and GSDMD p30 were cleaved possibly by caspase-3 as previously described32,39. Besides, ablation of Bid significantly reduced caspase-3 activation and GSDME maturation induced by nigericin (Fig. 10g). These results support the idea that caspase-1-induced apoptosis occurs in cell types that express no or a little GSDMD. Accordingly, the type of cell death induced after caspase-1 activation should be carefully examined, as it could be pyroptosis or apoptosis, depending on the expression of GSDMD.
Taken together with previous studies2,4,12,14,24,25, we propose a signaling network model for the cell death induced by inflammasomes (Supplementary Fig. 14). Our results indicate that caspase-1 can initiate apoptosis in the absence of GSDMD through Bid-dependent and Bid-independent pathways. The Bid-independent pathway was unmasked only in the absence of Bid. Early studies suggested that certain non-myeloid cells undergo caspase-1-dependent apoptotic cell death26,27,28,29. However, at present, caspase-1 is widely considered as an inflammatory caspase that initiates pyroptosis, probably because most of the recent studies on the inflammasome have been carried out using myeloid cells that abundantly express GSDMD. Thus, our current study provides an opportunity to revisit caspase-1-induced apoptosis and its pathophysiological functions.
Two reports on the role of caspase-1 in apoptotic signaling were recently published32,43. Taabazuing et al. demonstrated that Val-boroPro, a dipeptidyl peptidase (DPP) inhibitor, which induce a caspase-1-dependent cell death, induced apoptosis accompanied by caspase-3 and caspase-7 activation in GSDMD-deficient RAW264.7 and THP-1 cells32. They also demonstrated that recombinant caspase-1 cleaved caspase-3 and caspase-7 in a cell free system. However, whether the cleaved caspases were functional and whether the direct cleavage really happened in cells were not examined. Sagulenko et al. showed that the activation of the AIM2 inflammasome by DNA transfection induced caspase-3 activation even in caspase-8-deficient BMMs, and this caspase-3 activation was reduced when caspase-1 was knocked down43. These studies suggested that caspase-1 is involved in caspase-3 activation, although the mechanism of the pro-apoptotic action of caspase-1 remained unclear. Our results are consistent with these studies, and provide further conclusive evidence and molecular mechanisms for the caspase-1-induced apoptosis.
Not only caspase-1 but also caspase-8 is recruited to and activated in ASC specks in response to inflammasome activation24,25. This caspase-8 activation in ASC specks might have explained the inflammasome-induced apoptosis in GSDMD-deficient cells24,25. However, our results showed that the caspase-3 activation in response to inflammasome stimuli was higher in GSDMD-deficient than in caspase-1-deficient macrophages (Fig. 1d). He et al.20 reported similar observations using ASC-reconstituted RAW264.7 cells. It is thus possible that caspase-1 cooperates with caspase-8 to trigger apoptosis after inflammasome formation in ASC-expressing GSDMD-deficient cells. Furthermore, the caspase-8 activation induced in Gsdmd-KO CL26-iCasp1 cells and Gsdmd-KO RAW264.7 cells by AP20187 and S. Typhimurium, respectively, was diminished by the ablation of caspase-3 (Fig. 4c, e). Therefore, caspase-8 activation can occur not only in ASC specks, but also downstream of the caspase-1-caspase-3 axis (Supplementary Fig. 14). This finding is supported by the observation that the inflammasome-induced caspase-8 activation was greater in GSDMD-deficient than in caspase-1-deficient macrophages (Fig. 1d)20,44.
Although we demonstrated that Bid is required for caspase-1-initiated apoptosis, Bid is widely recognized as a caspase-8 substrate that mediates extrinsic apoptosis in type II cells2,45,46. In type I cells, caspase-8 directly activates effector caspases, whereas this mechanism is inefficient or not operational in type II cells. The expression of X-linked inhibitor of apoptosis protein (XIAP), an inhibitor of caspase-9 and effector caspases (caspase-3/7), in type II cells has been implicated in the latter phenomenon. Instead, in type II cells caspase-8-cleaved Bid (tBid) activates the intrinsic apoptosis pathway, in which mitochondria release proapoptotic proteins including cytochrome c, which activates caspase-9, and Smad, which relieves caspases from XIAP’s inhibition. We previously reported that apoptosis mediated by the ASC-caspase-8 axis follows the type I/type II−rule. Importantly, purified active caspase-1 is reported to cleave pro-caspase-3 in vitro47, although whether this occurs in cells needs to be confirmed. If caspase-1-mediated apoptosis also follows the type I/type II-rule, the requirement for Bid in this cell death pathway may differ according to cell type. Consistent with this possibility, CL26-iCasp1 cells are type II cells, as the TNF-induced apoptosis of the cells was Bid-dependent (Supplementary Fig. 15); however, it remains to be determined whether Bid is dispensable for the caspase-1-mediated apoptosis in type I cells.
The above discussion regarding the type I/type II rule may also be relevant to the Bid-independent pathway for caspase-1-initiated apoptosis in GSDMD-deficient cells, because (1) this Bid-independent pathway was inhibited by the cathepsin inhibitor CA-074Me (Fig. 8), and (2) cathepsins can play a role in apoptosis induction by degrading anti-apoptotic proteins including XIAP48. Therefore, a possible scenario is that in cells lacking both GSDMD and Bid, caspase-1 might directly or indirectly activate cathepsins, which in turn relieves caspases from XIAP’s inhibition, and then caspase-1 might directly activate effector caspases to induce apoptosis even in type II cells. These assumptions need to be tested in future investigations. In addition, caspase-1 has also been suggested to activate caspase-6 and caspase-749,50, which were not required for caspase-1’s induction of apoptosis in Bid-sufficient cells (Fig. 4f), but the involvement of these caspases in the Bid-independent pathway remains to be tested.
Our results suggest that GSDMD suppresses the caspase-1-induced caspase-3 activation in a manner dependent on its pore-forming activity (Fig. 2c). In particular, the caspase-3 activation was seen in Gsdmd-KO CL26-iCasp1 cells but not in WT CL26-iCasp1 cells 30 min after AP20187 treatment, at which time the WT cells were only partially lysed (Supplementary Fig. 3d, f). Therefore, it is unlikely that the caspase-3 activation was inhibited due to GSDMD-dependent cell disruption. We showed that ATP was released from GSDMD-expressing cells immediately after the activation of caspase-1 (Fig. 2g). ATP/dATP are theoretically small enough to pass through GSDMD-formed pores; thus, they are likely to diffuse through these pores. This could explain the attenuation of caspase-1-induced caspase-3 activation by GSDMD, because ATP/dATP are necessary for apoptosome formation51,52. In addition, tBid was also released after caspase-1 activation in a GSDMD-dependent manner (Fig. 6b). Strikingly, it has been demonstrated that active caspase-3 cleaves GSDMD to inactivate it32,39. Taken together, caspase-1-induced apoptosis and pyroptosis appear to suppress each other (Supplementary Fig. 14).
We propose that caspase-1-induced apoptosis occurs in cell types that do not or only weakly express GSDMD. Indeed, primary cortical neurons and mast cells underwent apoptosis in a caspase-1 and Bid-dependent manner (Fig. 10 and Supplementary Fig. 13). In mouse models of familial amyotrophic lateral sclerosis53,54,55 and ischemia-induced brain injury28,56, caspase-1 is reported to be involved in the disease pathogenesis, tBid generation, and caspase-3 activation in the spinal cord and the brain, respectively. Substantial amounts of caspase-1 and Bid, but no or little GSDMD, are expressed in the spinal cord (Supplementary Fig. 13). Accordingly, caspase-1-induced apoptosis is likely to participate in neurodegeneration under pathological conditions. Caspase-1-initiated apoptosis has also been implicated in UVB-induced apoptosis in human keratinocytes57, cisplatin-induced apoptosis in the kidney58, and hyperhomocysteinemia-induced endothelial apoptosis59. Interestingly, LPS-stimulated monocytes are reported to release microvesicles containing active caspase-1, which are taken up by different cells to deliver the cell death signal; for example, active caspase-1-containing microvesicles induce apoptosis in vascular smooth muscle cells and lymphocytes60,61. Hence, it may be speculated that caspase-1-induced apoptosis can occur in GSDMD-null cells in a non-cell-autonomous manner through the microvesicular transfer of active caspase-1 (Supplementary Fig. 13a). It is also reported that the 3 C protease of enterovirus 71 degrades GSDMD62, raising the possibility that microbial pathogens that stimulate inflammasome formation and inactivate GSDMD simultaneously induce caspase-1-mediated apoptosis (Supplementary Fig. 13a). Collectively, it is possible that caspase-1 initiates apoptosis in a variety of cell types in many situations.
Caspase-1, which was identified as IL-1β-converting enzyme (ICE) in 1992–199363,64,65, was suggested to induce apoptosis for the first time in 199326. The concept of pyroptosis was introduced in 20005; this concept is now widely accepted, whereas caspase-1-induced apoptosis has not received much attention. However, our results clearly demonstrated that this caspase has the potential to initiate both pyroptosis and apoptosis. The role of apoptosis, which is currently believed to be a silent cell death, initiated by caspase-1, the inflammatory cytokine-converting enzyme, remains to be unveiled. We hope that this study, which may represent a turning point in the understanding of the effector mechanisms of the inflammasome, will promote research on the pathophysiological roles of caspase-1 in different types of cells and tissues.
Wild-type C57BL/6 mice were purchased from Japan SLC. The Gsdmd−/− mice were generated previously66. The Casp1−/− mice67 carrying the 129-type nonfunctional Casp11 gene10 and the Pycard-/- mice68 were kindly provided by Dr. Winnie W. Wong (BASF Bioresearch Corporation) and Dr. Tetsuo Noda (Cancer Institute, Japanese Foundation for Cancer Research), respectively, and had been backcrossed to C57BL/6 mice. The Bid−/− mice69 were kindly provided by Dr. Tetsuo Takehara (Osaka University Graduate School of Medicine). The Gsdmd−/− Bid−/− mice were generated by crossing Gsdmd−/− mice and Bid−/− mice. Mice were bred and maintained in pathogen-free animal facilities at Kanazawa University, and were used between 10–20 weeks of age. The spinal cord was collected from mice perfused with cold Hanks’ balanced salt solution while anesthetized. The spleen, femurs, tibias, and peritoneal cells were harvested from mice after euthanasia. All animal experiments were approved by the Animal Care and Use Committee of Kanazawa University (AP-143305, AP-173853, AP-184013), and conducted in accordance with the Kanazawa University Animal Experimentation Regulations and the International Guiding Principles for Biomedical Research Involving Animals by the Council for International Organization of Medical Sciences and the international council for Laboratory animal science (December 2012).
Val-boroPro (MedChemExpress, HY-13233A); AP20187 (MedChemExpress, HY-13992); Poly dA:dT (Sigma-Aldrich, P0883); Lipopolysaccharides from Escherichia (E.) coli K-235 (Sigma-Aldrich, L2018); z-VAD-fmk (R&D Systems, FMK001); recombinant mouse M-CSF (R&D Systems, 416-ML); Bacto-thioglycolate medium without dextrose (Difco, 0363-17-2); SUPERFASLIGAND Protein (Enzo Life Sciences, ALX-522-020-C005); Recombinant Murine TNF-α (PeproTech, 315-01A); nigericin (Cayman CHEMICAL, 11437); and Puromycin aminonucleoside (Focus Biomolecules, 10-2101) were purchased. YO-PRO-1 Iodide (Y3603), Blasticidin S (R21001), and Geneticin (11811023) were purchased from Thermo Fisher Scientific. CA-074 Me (4323-v), E-64-d (4321-v), and Pepstatin A (4397-v) were purchased from Peptide Institute (Osaka, Japan).
Colon-26 cells (purchased from the RIKEN BioResource Center), RAW264.7 cells (kindly provided by Dr. Kensuke Miyake, Institute of Medical Science, University of Tokyo), and L929 cells (purchased from Cell Resource Center for Biomedical Research, Institute of Development, Aging and Cancer, Tohoku University) were grown in RPMI 1640 (Sigma-Aldrich) supplemented with 10% fetal bovine serum (FBS), 100 U ml−1 penicillin, and 100 μg ml−1 streptomycin under a humidified atmosphere with 5% CO2 at 37 °C. We confirmed that all the cell lines were free of mycoplasma contamination. Primary mouse bone marrow cells obtained from the femurs and tibias of 8–20-weeks-old mice were cultured in RPMI 1640 containing 10 ng ml−1 M-CSF or 10% L929 conditioned medium for 7 days, and adherent cells were used as BMMs. Primary mouse bone marrow cells were cultured in RPMI 1640 containing 50% WEHI-3 conditioned medium for 28 days, and floating cells were used as bone marrow-derived mast cells. TEPMs were collected from the peritoneal cavity of 8–10-week-old mice 4 days after the intraperitoneal injection of a 3.0-ml volume of 3% thioglycolate medium. 293FT cells (Invitrogen) were cultured in DMEM (Sigma-Aldrich) supplemented with 10% FBS, 100 U ml−1 penicillin, and 100 μg ml−1 streptomycin.
Primary cortical neuron culture and OGD
Mouse primary cortical neurons were prepared from embryonic day 15 mice with Neuron Dissociation Solutions (FUJIFILM Wako Pure Chemical Corporation, 291-78101). Neurons were plated on poly-L-lysine-coated 24-well plate and cultured in Neurobasal Medium (Themo Fisher Scientific, 21103049) containing 2% B27 supplement (Thermo Fisher Scientific, A3582801), 5% FBS, 0.5 mM L-Glutamine (WAKO, 076-00521), and 100 U ml−1 penicillin and streptomycin at a density of 2 × 105 per cm2. Cells were used for experiments on day 3 of culture. OGD on primary cortical neurons28 was performed as follows. The culture medium was replaced by glucose-free Earle’s balanced salt solution (Thermo Fisher Scientific, E2888), and the cells were placed in an anaerobic chamber with AnaeroPack (Mitsubishi Gas Chemical, A-04). Control cells were incubated in Earle’s balanced salt solution with glucose in a normoxic incubator. After 8 or 16 h, cells were fixed and subjected to immunofluorescence staining with anti-cleaved Caspase3 (Cell Signaling Technology, #9661), Anti-Tubulin Antibody, β III isoform (Merck, MAB1637), and DAPI (Thermo Fisher Scientific, D1306).
Induction of inflammasome formation
S. Typhimurium (ATCC 14028) (obtained from American Type Culture Collection) was grown in LB broth at 37 °C overnight, diluted 1:50 into fresh LB medium, and further grown for an additional 2.5 h with vigorous shaking. The optical density at 600 nm of the culture was measured to determine the CFU. The bacteria were then diluted in RPMI 1640 without antibiotics for infection. BMMs and RAW264.7 cells cultured in antibiotic-free RPMI1640 medium at a density of 5 × 104 well−1 in 96-well plates were infected with S. Typhimurium at an MOI of 5 and 40, respectively. The plates were centrifuged at 1500 × g for 5 min and then transferred to a CO2 incubator. After 1 h (BMMs) or 2 h (RAW264.7 cells), the cells were washed three times with antibiotic-free medium, and gentamicin (50 μg ml−1) was added to the wells. TEPMs were transfected with Poly dA:dT using Lipofectamine LTX (Thermo Fisher Scientific).
CRISPR/Cas9-mediated genome editing
Guide RNA (gRNA) sequences were designed and are listed in Supplementary Table 1. Oligonucleotide pairs were phosphorylated, annealed, and ligated into the BbsI site of eSpCas9(1.1) (Addgene, 71814) or pX330 (Addgene, 42230). The plasmids were extracted from E. coli cells, and endotoxin was removed using 1% Triton-X 114 (Nacalai Tesque). The plasmids were transfected into CL26-iCasp1 cells and RAW264.7 cells using Lipofectamine 3000 and the Neon transfection system (Thermo Fisher Scientific), respectively. The cells were cloned by limiting dilution 5 days after transfection, and the editing of target genes was tested by western blotting or sequencing of the gRNA-target sites. KO clones made with gRNA_1 and gRNA_2 targeting each gene are indicated by superscript KO1 and KO2, respectively.
Colon-26 and L929 cells expressing Fv3-caspases
pC4-Fv1E and pC4M-Fv2E were obtained from ARIAD, and pC4-Fv3E, which encodes three tandem FK506-binding protein Phe36Val (Fv) domains, was made by inserting the 654-bp XbaI-SpeI fragment from pC4M-Fv2E into the SpeI site of pC4-Fv1E. pC4-Fv3E was digested by BamHI and SpeI, and the HA-tag sequence was replaced with an oligonucleotide linker containing the HA-tag sequence and the BamHI and SpeI restriction sites to generate pC4-Fv3E-BS. PCR-amplified cDNAs of mouse caspase-1 and caspase-8 were cloned into pMOSBlue (GE Healthcare). The cDNA sequences excluding the stop codons were inserted into the BamHI and SpeI restriction sites of pC4-FV3E-BS, and the resulting plasmids encoded pro-caspases fused with three N-terminal Fv domains and a C-terminal HA-tag, herein called Fv3-caspases. The Fv3-caspase-coding sequences were then transferred into the EcoRI and SalI sites of the expression vector pEF-Bos. Colon-26 cells were co-transfected with each pEF-BOS- Fv3-caspase plasmid and a plasmid carrying the puromycin-resistance gene (pATM3-puro) using Lipofectamine 3000 (Thermo Fisher Scientific). The transfected cells were incubated with puromycin (10 μg ml−1) for 1 week and cloned by limiting dilution, and the Fv3-caspase-expressing clones were then selected. To generate the expression vector pLenti-T2A-BFP, Cas9-coding sequences were deleted from and a HpaI site was inserted into pLentiCas9-T2A-BFP (Addgene, 78547) by PCR and ligation using In-Fusion HD Cloning Kit (Clontech, 639650). Fv3-caspase-1-coding sequences were amplified by PCR and inserted into the HpaI site of pLenti-T2A-BFP. Lentiviruses were produced in 293FT cells (Thermo Fisher Scientific) that were co-transfected with lentiviral packaging vectors (pMD2.G and psPAX2 from Addgene) along with pLenti-Fv3-caspase-1-T2A-BFP or pLenti-T2A-BFP by the calcium phosphate method. The culture supernatant including lentiviral particles was collected, passed through a 0.45-μm filter, and stocked at −80 °C. L929 cells were transduced with the lentiviruses and cultured in the presence of blasticidin (10 μg ml−1) for 2 weeks to select for transduced cells, and the blue fluorescence-positive cells were isolated using a FACSAria II cell sorter (BD Biosciences).
Small interfering RNA (siRNA)-mediated knockdown
Bid was silenced using a MISSION esiRNA targeting mouse Bid (siBid_1; Sigma-Aldrich, EMU087401). The MISSION siRNA Universal Negative Control (Sigma-Aldrich, SIC-001) was used as a control siRNA for the siBid_1. Stealth RNAi siRNAs targeting mouse Gsdmd (MSS290579), mouse Bid (siBid_2 and siBid_3; MSS273392 and MSS273393, respectively), mouse Bax (MSS273360), and mouse Bak1 (MSS247040) were from Thermo Fisher Scientific. The Negative Universal control Med#3 (Thermo Fisher Scientific, 46-5373) was used as a control siRNA for the Stealth RNAi siRNAs. Cells were transfected with the siRNAs (50 nM) using Lipofectamine 3000 according to manufacturer’s instructions. The cells were used in experiments 2 days after transfection. In some experiments, siRNA transfection was repeated twice, and the cells were used 4 days after the first transfection. The efficiency of knockdown was confirmed by western blotting.
Separation of the cytoplasm fraction
Cells were suspended in mitochondria isolation buffer containing 3 mM HEPES-KOH (pH 7.4), 210 mM mannitol, 70 mM sucrose, 0.2 mM EGTA, and Protease Inhibitor Cocktail (Nacalai Tesque, 25955-11), and then homogenized using the Pestle Grinder System (Thermo Fisher Scientific, 03-392-106) on ice. After centrifugation (500 × g, 10 min, 4 °C), the supernatant was placed on an equal volume of 340 mM sucrose. Nuclei and unbroken cells were removed as the pellet by centrifugation at 500 × g, 10 min, 4 °C. The supernatant was transferred to a new tube and centrifuged at 10,000 × g, 10 min, 4 °C to remove mitochondria as the pellet. The supernatant was collected in another tube and used as the cytoplasm fraction.
Caspase-3/7 assay and ATP measurement
The caspase-3/7 activity in cell lysates was assayed using the Caspase-3/7-Glo luminescent kit (Promega, G8091). Cells were lysed in TBS containing 1% Triton-X 100 and 1 mM DTT, and 30 μl of the cell lysate was incubated with an equal volume of the reagent in a white 96-well plate for 5 min at room temperature. Luminescence values were measured with the Tecan Infinite M200 plate reader equipped for luminescence detection. The ATP level in culture supernatants was measured using the Cell ATP assay reagent (Toyo-ink, 304-15361). The culture supernatants were heated at 95 °C for 10 min to inactivate ATPases immediately after collection, then 30 μl of supernatant was mixed with an equal volume of the reagent in a white 96-well plate. Luminescence was measured as described above. The amount of ATP was calculated by generating an ATP standard curve.
LDH release assay
The LDH released from cells into culture supernatants was measured using the CytoTox 96 Non-Radioactive Cytotoxicity Assay (Promega, G1780) according to the manufacturer’s protocol. The percentage of LDH release was calculated as follows: % LDH release = (sample LDH activity-background LDH)(total LDH activity- background LDH)−1 × 100.
Cells were stained with annexin V-Cy5 (BioVision, 1013; 1:1000 dilution) and propidium iodide (Immuno Chemistry Technologies, 638; 1:500 dilution) in annexin V binding buffer containing 10 mM HEPES (pH 7.4), 150 mM NaCl, 5 mM KCl, 1 mM MgCl2, and 1.8 mM CaCl2 for 15 min on ice. To assess mitochondrial membrane potential, cells were stained with 100 nM tetramethylrhodamine methlester (TMRM; Thermo Fisher Scientific, T668) in culture medium for 15 min room temperature. Bone marrow-derived mast cells suspended in staining buffer (PBS, 1% BSA, 0.1% NaN3) were pretreated with TruStain fcX (BioLegend, 101320) at 4 °C for 30 min and then stained with APC anti-mouse CD117 (BioLegend, 105811) and FITC anti-mouse FcεRIα (BioLegend, 134305) at 4 °C for 30 min. The cells were analyzed by flow cytometry using a FACSCanto II flow cytometer (BD Biosciences), and data were analyzed using FlowJo V10 software.
Cells were solubilized in SDS-Sample Buffer containing 20 mM DTT and boiled at 95 °C for 20 min. The spinal cord and TEPMs were lysed in TBS containing 1% Triton-X 100, 2 mM EDTA, and Protease Inhibitor Cocktail (Nacalai Tesque, 25955-11), and the protein concentration in the samples was assayed using the Pierce BCA Protein Assay Kit (23225) before solubilization in SDS-Sample Buffer. The samples were subjected to SDS–PAGE and transferred to PVDF membranes (Merck). The membranes were blocked with Blocking One (Nacalai Tesque) for 1 h at room temperature, and then incubated overnight at 4 °C with the following primary antibodies diluted in Immuno-enhancer Reagent A (Wako, 295-68614): cleaved Caspase3 (#9661, 1:1000), Caspase-3 (#9665, 1:1000), Caspase-6 (#9762, 1:500), Caspase-7 (#12827, 1:500), cleaved Caspase-8 (#8592, 1:500), Caspase-8 (#4790, 1:1000), Caspase-9 (#9504, 1:1000), Bid (#2003, 1:500), RIPK3 (#15828, 1:1000), and Cytochrome c (#4272, 1:500), Apaf-1 (#8969, 1:1000) from Cell Signaling Technology; MTCO1 (ab14705, 1:1000), GSDME (ab215191, 1:1000), GSDMD (ab209845, 1:1000), Caspase-1 (ab179515, 1:1000) from Abcam; Caspase-1 (sc-514, 1:1000) and GSDMD (sc-393581, 1:400) from Santa Cruz Biotechnology; Caspase-2 (MAB3507, 1:500) from Merck; and GAPDH (M171-3, 1:1000) from Medical & Biological Laboratories. The following secondary antibodies diluted in Immuno-enhancer Reagent B (Wako, 292-68624) were used: anti-rabbit IgG HRP-linked antibody (#7074, 1:1000), anti-mouse IgG HRP-linked antibody (#7076, 1:1000), and anti-rat IgG HRP-linked antibody (#7077, 1:1000) from Cell Signaling Technology. Most of Western blotting analyses were performed by an experimenter who was blinded to the samples. Uncropped scans of western blots are shown in Supplementary Fig. 16.
Total RNA was isolated from the spinal cord, spleen, and RAW264.7 cells using TRIzol Reagent (Thermo Fisher Scientific, 15596026) and reverse transcribed to produce cDNA with the SuperScript VILO cDNA Synthesis Kit (Thermo Fisher Scientific, 11754050) according to the manufacturer’s instructions. Quantitative RT-PCR reactions were performed using the Express SYBR GreenER qPCR Super Mix (Thermo Fisher Scientific) and ViiA7 Real-Time PCR System (Thermo Fisher Scientific). The primers used for quantitative RT-PCR are as listed in Supplementary Table 1.
A multiple cloning site was inserted into the XbaI and BstBI sites of pLenti6/V5-DEST (Thermo Fisher Scientific) to generate pLenti6EB. The 778-bp EcoRI-XbaI fragment of pEGFP-N3 (Clontech) was inserted into the EcoRI and XbaI sites of pLenti6EB to generate pLenti6EB-GFP. The cDNA of mouse GSDMD was reverse transcribed from spleen RNA, amplified by RT-PCR, and cloned into pCR-Blunt (Thermo Fisher Scientific). The GSDMD I105N mutant was generated by site-directed mutagenesis. GSDMD-encoding sequences were amplified by PCR from the pCR-Blunt plasmids, digested by EcoRI, and inserted into the EcoRI site of pLenti6EB-GFP. Lentiviruses were produced in 293FT cells that were co-transfected with lentiviral packaging vectors (pLP1, pLP2, and pLP/VSV-G from Thermo Fisher Scientific) along with pLenti6EB-GSDMD-GFP or pLenti6EB-GSDMD I105N-GFP. Gsdmd-KO CL26-iCasp1 cells were transduced with the lentiviruses and cultured in the presence of blasticidin (2 μg ml−1) for 2 weeks to select for transduced cells, and the EGFP-positive cells were isolated using a FACSAria II cell sorter. The cDNA of mouse Bid was obtained from Addgene (#3278), and mutations were introduced by site-directed mutagenesis. The plasmids were digested by EcoRI, and the Bid-encoding 624-bp DNA fragments were inserted into the EcoRI site of pEGFP-C3 (Clontech). These plasmids were transfected into Gsdmd/Bid-DKO CL26-iCasp1 cells using Lipofectamine 3000. After selection with geneticin (500 μg ml−1), the EGFP-positive cells were isolated using a FACSAria II cell sorter. Caspase-9 cDNA was amplified by PCR from mouse spleen cDNA and inserted into HpaI-digested pLenti-T2A-BFP using In-Fusion HD Cloning Kit. pLenti-Casp9-T2A-BFP was used to produce lentiviruses, and Gsdmd/Casp9-DKO CL26-iCasp1 cells were transduced with the viruses, as mentioned above. The GSDMD-encoding sequence except for the stop codon were amplified by PCR, digested by MluI, and inserted into the MluI site of pL-SFFV.Reporter.RFP657.PAC (Addgene, 61395). L929-iCasp1 cells were transduced with viruses produced in 293FT cells that were co-transfected with pL-SFFV.Reporter.RFP657.PAC-GSDMD, pMD2.G, and psPAX2. The transduced cells were selected in the presence of puromycin (2 μg ml−1) for 2 weeks, and the red fluorescence-positive cells were isolated using a FACSAria II cell sorter.
Gsdmd-KO CL26-iCasp1 cells were transfected with pCDNA3.1-SCAT337 using Lipofectamine 3000. After selection with geneticin (500 μg ml−1), the Venus-positive cells were isolated using a FACSAria II cell sorter.
Microscopy and time-lapse imaging
Light micrographs of cells were captured using a digital camera (Olympus, DP21) mounted on an inverted microscope (Olympus, CKX41). Time-lapse imaging was performed using a fluorescence microscope (Keyence, BZ-9000). Cells were treated with 50 nM AP20187 in the presence or absence of Yo-Pro-1 (1:1000 dilution) at 37 °C in a humidified atmosphere of 5% CO2 in air. The YO-PRO-1, CFP, and CFP-Venus FRET images were acquired through a GFP filter set (Keyence, OP-87763), a CFP filter set (Chroma, 49001), and a CFP-YFP FRET filter set (Chroma, 49052), respectively. Microscopic images of cells were randomly selected from sample cultures, while magnified images of representative cells with normal, necrotic or apoptotic morphology are also shown.
CL26-iCasp1 cells were plated at a density of 106 cells per 10 cm plate and incubated overnight. The cells were treated with or without 50 nM of AP20187 for 1 h, washed with PBS twice, and lysed in 0.5 ml lysis buffer (0.5% Nonidet P-40, 50 mM HEPES pH7.4, 150 mM NaCl, 10% glycerol, 2 mM EDTA, 1 mM DTT) containing Protease Inhibitor Cocktail and Phosphatase Inhibitor Cocktail (Nacalai Tesque, 03969-21) on ice for 10 min. The cell lysates were cleared by centrifugation for 15 min at 20000 × g at 4 °C and then reacted with anti-caspase-9 antibody (CST, #9504, 1:150) for 2 h at 4 °C with gentle rotation. Protein G Sepharose beads (GE Healthcare, 17-0618-02) were washed with three times lysis buffer and added to the cell lysate and antibody mixture (20 μl of 50% slurry per plate). The mixture was gently rotated for 2 h at 4 °C, and the beads were centrifuged and washed five times with lysis buffer. The immunoprecipitated proteins were eluted by adding 100 μl SDS-Sample Buffer containing 20 mM DTT and heating at 95 °C for 5 min.
Cell viability was determined by a colorimetric assay using 2-(4-iodophenyl)-3-(4-nitrophenyl)-5-(2, 4-disulfophenyl)-2H-tetrazolium monosodium salt (WST-1; Dojindo, W201) and 1-methoxy-5-methylphenazinium methylsulfate (1-Methoxy PMS; Dojindo, M003). WST-1 and 1-Methoxy PMS were dissolved in PBS at 10 mM and 0.4 mM, respectively. Equal volumes of the solutions were mixed, and the mixture was added to cell cultures (10 μl per 100 μl culture medium). The cells were incubated for 2 h, culture supernatants were transferred to a 96-well plate, and the net absorbance at 450 nm was measured using a microplate reader.
Gentamicin protection assay
Macrophages were infected with S. Typhimurium and treated with gentamicin as mentioned above. The cells were washed with PBS and lysed in 0.1X PBS/0.05% Triton X-100. The cell lysates were serially diluted with PBS/1% glycerol and plated on LB agar. Plates were incubated at 37 °C overnight, and colonies were counted.
The URLs for web resources used in this study are as follows: BioGPS, http://biogps.org/#goto=welcome; GNF Mouse GeneAtlas V3 (GeneAtlas MOE430, gcrma), https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE10246.70
Sample size was determined according to our experience and literature reporting similar experiments. Normality and variance were not examined, because sample size is too small to have sufficient power. Data were analyzed by a two-tailed unpaired t-test or two-way analysis of variance with Bonferroni’s post-test, depending on the number of groups being compared. GraphPad Prism software 6.0 was used for the statistical analyses. A p-value less than 0.05 was considered to be statistically significant.
All data supporting the findings of this study are available within the article and its Supplementary Information files or are available from the corresponding authors upon reasonable request. The source data underlying Figs. 1a, b, 2b, d, g, 3b, f, 4g, i, 5b–d, 6c, d, f, 7e, 8c–f, 9b, e, 10a, b, d, and Supplementary Figs. 2c, 3b, c, e, f, 4b, d–g, 5d–f, 6a, b, 7a, b, 8a, c, d, f, 9b–d, 10d, 11a, b, 12c, d, 13d, e, and 15 are provided as a Source Data file. Uncropped scans of western blots are shown in Supplementary Fig. 16.
Journal peer review information: Nature Communications would like to thank the anonymous reviewer for their contribution to the peer review of this work. Peer review reports available.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Shalini, S., Dorstyn, L., Dawar, S. & Kumar, S. Old, new and emerging functions of caspases. Cell Death Differ. 22, 526–539 (2015).
Galluzzi, L., et al. Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ. https://doi.org/10.1038/s41418-017-0012-4. (2018)
Nagata, S. & Tanaka, M. Programmed cell death and the immune system. Nat. Rev. Immunol. 17, 333–340 (2017).
Malik, A. & Kanneganti, T. D. Inflammasome activation and assembly at a glance. J. Cell Sci. Dec 130, 3955–3963 (2017).
Cookson, B. T. & Brennan, M. A. Pro-inflammatory programmed cell death. Trends Microbiol. 9, 113–114 (2001).
Fink, S. L. & Cookson, B. T. Caspase-1-dependent pore formation during pyroptosis leads to osmotic lysis of infected host macrophages. Cell Microbiol. 8, 1812–1825 (2006).
Miao, E. A. et al. Caspase-1-induced pyroptosis is an innate immune effector mechanism against intracellular bacteria. Nat. Immunol. 11, 1136–1142 (2010).
Jorgensen, I., Zhang, Y., Krantz, B. A. & Miao, E. A. Pyroptosis triggers pore-induced intracellular traps (PITs) that capture bacteria and lead to their clearance by efferocytosis. J. Exp. Med. 213, 2113–2128 (2016).
Zhu, S. et al. Nlrp9b inflammasome restricts rotavirus infection in intestinal epithelial cells. Nature 546, 667–670 (2017).
Kayagaki, N. et al. Non-canonical inflammasome activation targets caspase-11. Nature 479, 117–121 (2011).
Doitsh, G. et al. Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection. Nature 505, 509–514 (2014).
Tsuchiya, K. & Hara, H. The inflammasome and its regulation. Crit. Rev. Immunol. 34, 41–80 (2014).
Roberts, T. L. et al. J. HIN-200 proteins regulate caspase activation in response to foreign cytoplasmic DNA. Science 323, 1057–1060 (2009).
Broz, P., von Moltke, J., Jones, J. W., Vance, R. E. & Monack, D. M. Differential requirement for Caspase-1 autoproteolysis in pathogen-induced cell death and cytokine processing. Cell Host Microbe. 8, 471–483 (2010).
Kayagaki, N. et al. Noncanonical inflammasome activation by intracellular LPS independent of TLR4. Science. 341, 1246–1249 (2013).
Hagar, J. A., Powell, D. A., Aachoui, Y., Ernst, R. K. & Miao, E. A. Cytoplasmic LPS activates caspase-11: implications in TLR4-independent endotoxic shock. Science 341, 1250–1253 (2013).
Shi, J. et al. Inflammatory caspases are innate immune receptors for intracellular LPS. Nature 514, 187–192 (2014).
Shi, J. et al. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature 526, 660–665 (2015).
Kayagaki, N. et al. Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling. Nature 526, 666–671 (2015).
He, W. T. et al. Gasdermin D is an executor of pyroptosis and required for interleukin-1β secretion. Cell Res. 25, 1285–1298 (2015).
Ding, J. et al. Pore-forming activity and structural autoinhibition of the gasdermin family. Nature 535, 111–116 (2016).
Liu, X. et al. Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores. Nature 535, 153–158 (2016).
Aglietti, R. A. et al. GsdmD p30 elicited by caspase-11 during pyroptosis forms pores in membranes. Proc. Natl Acad. Sci. USA 113, 7858–7863 (2016).
Hasegawa, M. et al. Mechanism of ASC-mediated apoptosis: bid-dependent apoptosis in type II cells. Oncogene. 26, 1748–1756 (2007).
Sagulenko, V. et al. AIM2 and NLRP3 inflammasomes activate both apoptotic and pyroptotic death pathways via ASC. Cell Death Differ. 20, 1149–1160 (2013).
Miura, M., Zhu, H., Rotello, R., Hartwieg, E. A. & Yuan, J. Induction of apoptosis in fibroblasts by IL-1 beta-converting enzyme, a mammalian homolog of the C. elegans cell death gene ced-3. Cell. 75, 653–660 (1993).
Nalin, C. M. Apoptosis research enters the ICE age. Structure. 3, 143–145 (1995).
Zhang, W. H. et al. Fundamental role of the Rip2/caspase-1 pathway in hypoxia and ischemia-induced neuronal cell death. Proc. Natl Acad. Sci. USA 100, 16012–16017 (2003).
Syed, F. M. et al. Proapoptotic effects of caspase-1/interleukin-converting enzyme dominate in myocardial ischemia. Circ. Res. 96, 1103–1109 (2005).
Mariathasan, S. et al. Differential activation of the inflammasome by caspase-1 adaptors ASC and Ipaf. Nature 430, 213–218 (2004).
Pelegrin, P., Barroso-Gutierrez, C. & Surprenant, A. P2X7 receptor differentially couples to distinct release pathways for IL-1beta in mouse macrophage. J. Immunol. 180, 7147–7157 (2008).
Taabazuing, C. Y., Okondo, M. C. & Bachovchin, D. A. Pyroptosis and Apoptosis Pathways Engage in Bidirectional Crosstalk in Monocytes and Macrophages. Cell Chem. Biol. 24, 507–514 (2017).
Okondo, M. C. et al. DPP8 and DPP9 inhibition induces pro-caspase-1-dependent monocyte and macrophage pyroptosis. Nat. Chem. Biol. 13, 46–53 (2017).
Mallet, V. O. et al. Conditional cell ablation by tight control of caspase-3 dimerization in transgenic mice. Nat. Biotechnol. 20, 1234–1239 (2002).
Pajvani, U. B. et al. Fat apoptosis through targeted activation of caspase 8: a new mouse model of inducible and reversible lipoatrophy. Nat. Med. 11, 797–803 (2005).
Susin, S. A. et al. Two distinct pathways leading to nuclear apoptosis. J. Exp. Med. 192, 571–580 (2000).
Cregan, S. P., Dawson, V. L. & Slack, R. S. Role of AIF in caspase-dependent and caspase-independent cell death. Oncogene. 23, 2785–2796 (2004).
Takemoto, K., Nagai, T., Miyawaki, A. & Miura, M. Spatio-temporal activation of caspase revealed by indicator that is insensitive to environmental effects. J. Cell Biol. 160, 235–243 (2003).
Rogers, C. et al. Cleavage of DFNA5 by caspase-3 during apoptosis mediates progression to secondary necrotic/pyroptotic cell death. Nat. Commun. 8, 14128 (2017).
Wang, Y. et al. Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin. Nature 547, 99–103 (2017).
Lee, B. L. et al. ASC- and caspase-8-dependent apoptotic pathway diverges from the NLRC4 inflammasome in macrophages. Sci. Rep. 8, 3788 (2018).
Li, H., Zhu, H., Xu, C. J. & Yuan, J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 94, 491–501 (1998).
Sagulenko, V., Vitak, N., Vajjhala, P. R., Vince, J. E. & Stacey, K. J. Caspase-1 Is an Apical Caspase Leading to Caspase-3 Cleavage in the AIM2 Inflammasome Response, Independent of Caspase-8. J. Mol. Biol. 430, 238–247 (2018).
Schneider, K. S. et al. The Inflammasome Drives GSDMD-Independent Secondary Pyroptosis and IL-1 Release in the Absence of Caspase-1 Protease Activity. Cell Rep. 21, 3846–3859 (2017).
Kantari, C. & Walczak, H. Caspase-8 and bid: caught in the act between death receptors and mitochondria. Biochim. Biophys. Acta. 1813, 558–563 (2011).
Jost, P. J. et al. XIAP discriminates between type I and type II FAS-induced apoptosis. Nature 460, 1035–1039 (2009).
Van de Craen, M., Declercq, W., Van den Brande, I., Fiers, W. & Vandenabeele, P. The proteolytic procaspase activation network: an in vitro analysis. Cell Death Differ. 6, 1117–61124 (1999).
Droga-Mazovec, G. et al. Cysteine cathepsins trigger caspase-dependent cell death through cleavage of bid and antiapoptotic Bcl-2 homologues. J. Biol. Chem. 283, 19140–19150 (2008).
Lamkanfi, M. et al. Targeted peptidecentric proteomics reveals caspase-7 as a substrate of the caspase-1 inflammasomes. Mol. Cell Proteomics. 7, 2350–2363 (2008).
Guo, H. et al. Caspase-1 activation of caspase-6 in human apoptotic neurons. Cell Death Differ. 13, 285–292 (2006).
Li, P. et al. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 91, 479–489 (1997).
Hu, Y., Benedict, M. A., Ding, L. & Núñez, G. Role of cytochrome c and dATP/ATP hydrolysis in Apaf-1-mediated caspase-9 activation and apoptosis. EMBO J. 18, 3586–3595 (1999).
Li, M. et al. Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse model. Science 288, 335–339 (2000).
Pasinelli, P., Houseweart, M. K., Brown, R. H. Jr. & Cleveland, D. W. Caspase-1 and -3 are sequentially activated in motor neuron death in Cu,Zn superoxide dismutase-mediated familial amyotrophic lateral sclerosis. Proc. Natl Acad. Sci. USA 97, 13901–13906 (2000).
Guégan, C. et al. Instrumental activation of bid by caspase-1 in a transgenic mouse model of ALS. Mol. Cell Neurosci. 20, 553–662 (2002).
Schielke, G. P., Yang, G. Y., Shivers, B. D. & Betz, A. L. Reduced ischemic brain injury in interleukin-1 beta converting enzyme-deficient mice. J. Cereb. Blood Flow Metab. 18, 180–185 (1998).
Sollberger, G. et al. Caspase-1 activity is required for UVB-induced apoptosis of human keratinocytes. J. Invest. Dermatol. 135, 1395–1404 (2015).
Faubel, S. et al. Caspase-1-deficient mice are protected against cisplatin-induced apoptosis and acute tubular necrosis. Kidney Int. 66, 2202–2213 (2004).
Xi, H. et al. Caspase-1 inflammasome activation mediates homocysteine-induced pyrop-apoptosis in endothelial cells. Circ. Res. 118, 1525–1539 (2016).
Sarkar, A., Mitra, S., Mehta, S., Raices, R. & Wewers, M. D. Monocyte derived microvesicles deliver a cell death message via encapsulated caspase-1. PLoS ONE 4, e7140 (2009).
Exline, M. C. et al. Microvesicular caspase-1 mediates lymphocyte apoptosis in sepsis. PLoS ONE 9, e90968 (2014).
Lei, X. et al. Enterovirus 71 inhibits pyroptosis through cleavage of gasdermin D. J. Virol. 91, e01069–17 (2017). pii.
Cerretti, D. P. et al. Molecular cloning of the interleukin-1 beta converting enzyme. Science 256, 97–100 (1992).
Thornberry, N. A. et al. A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes. Nature 356, 768–774 (1992).
Yuan, J., Shaham, S., Ledoux, S., Ellis, H. M. & Horvitz, H. R. The C. elegans cell death gene ced-3 encodes a protein similar to mammalian interleukin-1 beta-converting enzyme. Cell 75, 641–652 (1993).
Fujii, T. et al. Gasdermin D (Gsdmd) is dispensable for mouse intestinal epithelium development. Genesis. 46, 418–323 (2008).
Li, P. et al. Mice deficient in IL-1 beta-converting enzyme are defective in production of mature IL-1 beta and resistant to endotoxic shock. Cell 80, 401–411 (1995).
Yamamoto, M. et al. ASC is essential for LPS-induced activation of procaspase-1 independently of TLR-associated signal adaptor molecules. Genes Cells 9, 1055–1067 (2004).
Yin, X. M. et al. Bid-deficient mice are resistant to Fas-induced hepatocellular apoptosis. Nature 400, 886–891 (1999).
Lattin, J. E. et al. Expression analysis of G protein-coupled receptors in mouse macrophages. Immunome Res. 4, 5 (2008).
This work was supported by Grant-in-Aid for Scientific Research on Innovative Areas (KAKENHI Grant Number 26110002) and by Grant-in-Aid for Challenging Exploratory Research (KAKENHI Grant Number 15K15078) from the Japan Society for the Promotion of Science (to T. Suda). This work was also supported by the Japan Society for the Promotion of Science (KAKENHI Grant Number 26460523) and the Institute for Frontier Science Initiative (InFiniti), Kanazawa University (to K.T.).